Type(s) of Cancer
Leukemia/Lymphoma
Leukemia/Lymphoma
Study Phase
Phase 3
Study Completion Date
December 2022
December 2022
NCT02883049Uploaded 04-27-2021
Access via NCI by Request
PDS UID: nci-data-466
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Files: NCT02883049-D1



Data DictionaryNCT02883049-D1-Data-Dictionary_2.pdf

DATANCT02883049-D1-Dataset_1.csv

OTHERREADME.pdf
Files: NCT02883049-D2



Data DictionaryNCT02883049-D2-Data-Dictionary_3.pdf

DATANCT02883049-D2-Dataset_1.csv

OTHERREADME.pdf
Files: NCT02883049-D3



Data DictionaryNCT02883049-D3-Data-Dictionary_2.pdf

DATANCT02883049-D3-Dataset.csv

OTHERREADME.pdf